<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35788">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640664</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002H2301E1</org_study_id>
    <nct_id>NCT02640664</nct_id>
  </id_info>
  <brief_title>Rainbow Extension Study</brief_title>
  <acronym>RainbowExt</acronym>
  <official_title>RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long term efficacy and safety of intravitreal
      ranibizumab compared with laser ablation therapy in patients who were treated for
      retinopathy of prematurity (ROP) in the core study CRFB002H2301
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual function</measure>
    <time_frame>at the patient's fifth birthday</time_frame>
    <description>Visual acuity in the better-seeing eye</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients having any ocular Adverse Event</measure>
    <time_frame>at the patient's fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients having any systemic Adverse Event</measure>
    <time_frame>at the patient's fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual function</measure>
    <time_frame>at the patient's fifth birthday</time_frame>
    <description>Visual acuity in the worse-seeing eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of active Retinopathy of Prematurity (ROP)</measure>
    <time_frame>40 weeks and 52 weeks after initial study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of ocular structural abnormalities</measure>
    <time_frame>40 weeks after initial study treatment, at the patient's 2 years corrected age and fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of ROP</measure>
    <time_frame>40 weeks and 52 weeks after initial study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ranibizumab administrations</measure>
    <time_frame>40 weeks after initial study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refraction in each eye</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing/sitting height and leg length</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference</measure>
    <time_frame>at the patient's 2 years' corrected age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
    <description>Percentage of patients with oxygen supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing function</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
    <description>Percentage of patients with presence of hearing impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight at first hospital discharge</measure>
    <time_frame>at the patient's 2 years' corrected age and fifth birthday</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab 0.1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab 0.2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Laser therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.2 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections</description>
    <arm_group_label>Ranibizumab 0.2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.1 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections</description>
    <arm_group_label>Ranibizumab 0.1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient successfully completed the core study CRFB002H2301

          -  The patient received study treatment in both eyes at baseline of study CRFB002H2301

        Exclusion Criteria:

          -  Patient has a medical condition or personal circumstance which precludes study
             participation or compliance with study procedures, as assessed by the Investigator

          -  Patient has been discontinued from the core study CRFB002H2301 at any time

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Estonia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>December 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open-label, long-term, extension study</keyword>
  <keyword>intravitreal ranibizumab</keyword>
  <keyword>laser ablation therapy</keyword>
  <keyword>retinopathy of prematurity</keyword>
  <keyword>preterm infants</keyword>
  <keyword>RAINBOW</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
